1. A nutritional composition comprising:
a. eicosapentaenoic acid (EPA) andor arachidonic acid (ARA), wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 15 wt. % of the total fat content; and
b. at least two distinct oligosaccharides with a degree of polymerisation (DP) between 2 and 60 comprising transgalactooligosaccharide (TOS) and inulin in a 9:1 (ww) ratio, respectively.
2. The composition according to claim 1, wherein at least 10 wt. % of the oligosaccharides has a degree of polymerisation (DP) between 2 to 5 and at least 5 wt. % of the oligosaccharides has a DP between 10 and 60.
3. The composition according to claim 1, further comprising an acidic oligosaccharide with a DP between 2 and 60.
4. The composition according to claim 1, comprising EPA.
5. The composition according to claim 1, further comprising DHA.
6. The composition according to claim 2, further comprising an acidic oligosaccharide with a DP between 2 and 60.
7. The composition according to claim 3, wherein the acidic oligosaccharide is an uronic acid polymer with a DP between 2 and 6.
8. The composition according to claim 1, comprising 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat, wherein said protein comprises hydrolyzed milk protein, vegetable protein, amino acids, or combinations thereof.
9. The composition according to claim 2, comprising 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat, wherein said protein comprises hydrolyzed milk protein, vegetable protein, amino acids, or combinations thereof.
10. The composition according to claim 3, comprising 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat, wherein said protein comprises hydrolyzed milk protein, vegetable protein, amino acids, or combinations thereof.
11. The composition according to claim 4, comprising 7.5 to 12.5 energy % protein; 40 to 55 energy % carbohydrates; and 35 to 50 energy % fat, wherein said protein comprises hydrolyzed milk protein, vegetable protein, amino acids, or combinations thereof.
12. The composition according to claim 1 having a caloric content of 0.6 to 0.8 kcalml; an osmolality of 50 to 500 mOsmkg; and a viscosity below 50 mPas.
13. The composition according to claim 2 having a caloric content of 0.6 to 0.8 kcalml; an osmolality of 50 to 500 mOsmkg; and a viscosity below 50 mPas.
14. The composition according to claim 3 having a caloric content of 0.6 to 0.8 kcalml; an osmolality of 50 to 500 mOsmkg; and a viscosity below 50 mPas.
15. The composition according to claim 4 having a caloric content of 0.6 to 0.8 kcalml; an osmolality of 50 to 500 mOsmkg; and a viscosity below 50 mPas.
16. The composition according to claim 8 having a caloric content of 0.6 to 0.8 kcalml; an osmolality of 50 to 500 mOsmkg; and a viscosity below 50 mPas.
17. The composition according to claim 1, wherein:
a. the content of long chain polyunsaturated fatty acid is below 3 wt. % of the total fat content;
b. the content of omega-3 long chain polyunsaturated fatty acid is below 1 wt. % of the total fat content; and
c. the content of omega-6 long chain polyunsaturated fatty acid is below 2 wt. % of the total fat content.
18. A method for stimulating intestinal barrier integrity, comprising administering to a mammal a composition comprising:
a. eicosapentaenoic acid (EPA) andor arachidonic acid (ARA), wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 15 wt. % of the total fat content; and
b. at least two distinct oligosaccharides with a degree of polymerisation (DP) between 2 and 60 comprising transgalactooligosaccharide (TOS) and inulin in a 9:1 (ww) ratio, respectively.
19. A method for the treatment of allergy comprising administering to a mammal a composition comprising:
a. eicosapentaenoic acid (EPA) andor arachidonic acid (ARA), wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 15 wt. % of the total fat content; and
b. at least two distinct oligosaccharides with a degree of polymerisation (DP) between 2 and 60 comprising transgalactooligosaccharide (TOS) and inulin in a 9:1 (ww) ratio, respectively.
20. A method for the treatment of diarrhea comprising administering to a mammal a composition comprising:
a. eicosapentaenoic acid (EPA) andor arachidonic acid (ARA), wherein the content of long chain polyunsaturated fatty acid with 20 and 22 carbon atoms does not exceed 15 wt. % of the total fat content; and
b. at least two distinct oligosaccharides with a degree of polymerisation (DP) between 2 and 60 comprising transgalactooligosaccharide (TOS) and inulin in a 9:1 (ww) ratio, respectively.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A curable epoxy resin composition, comprising:
(a) at least one or more epoxy resins having an average of more than one glycidyl ether group per molecule;
(b) one or more sterically hindered amine functional curing agents having at least two sterically hindered amine functional goups per molecule; and
(c) one or more non-sterically hindered amine functional curing agents having at least two non-sterically hindered amine groups per molecule.
2. The curable composition of claim 1, wherein the combination of sterically hindered amine functional curing agents and non-sterically hindered amine functional curing agents are present in a sufficient amount to increase the fracture toughness of the resultant cured product made from the curable epoxy resin composition while maintaining other thermo-mechanical properties of the resultant cured product.
3. The curable composition of claim 1, including (d) a co-curing agent different from the sterically hindered amine curing agent; and wherein the co-curing agent (d) different from the sterically hindered amine curing agent, is a non-sterically hindered amine having more than one reactive hydrogen per molecule.
4. The curable composition of claim 1, including (e) a second epoxy resin different from the epoxy resin component (a); and wherein the second epoxy resin (e) comprises 1,4 butanediol diglycidylether.
5. The curable composition of claim 3, wherein the epoxy resin (a) ranges from about 15 percent by weight to about 90 percent by weight of the curable composition; wherein the sterically hindered amine curing agent (b) ranges from about 5 percent by weight to about 25 percent by weight of the curable composition; wherein the non-sterically hinder amine functional curing agent (c) ranges from about 1 percent by weight to about 65 percent by weight of the curable composition; and wherein the co-curing agent (d) different from the sterically hindered amine functional curing agent ranges from about 1 percent by weight to about 65 percent by weight of the curable composition.
6. The curable composition of claim 1, further comprising from about 1 percent by weight to about 80 percent by weight of a reinforcing material (f); and wherein the reinforcing material (f) comprises glass fibers.
7. The curable composition of claim 1, further comprising from about 1 percent by weight to about 80 percent by weight of a filler material (g); and wherein the filler (g) comprises calcium carbonate.
8. The curable composition of claim 1, wherein the epoxy resin comprises a cycloaliphatic diepoxide, a diepoxide of divinylbenzene, a diglycidylether of a phenolic or an alcoholic compound, diglycidylether of bisphenol A, or 1,4 butanedioldiglycidylether; or wherein the epoxy resin is made by a peroxidation of an unsaturated compound process; or the reaction product of (i) epihalohydrin and (ii) a phenolic or an alcoholic compound.
9. The curable composition of claim 1, wherein the sterically hindered amine curing agent comprises poly(oxypropylene)diamine; and wherein the non-sterically hindered amine curing agent comprises diethylenetriamine.
10. A process for preparing a curable epoxy resin composition comprising admixing:
(a) at least one or more epoxy resins having an average of more than one glycidyl ether group per molecule;
(b) one or more sterically hindered amine functional curing agents having at least two sterically hindered amine functional groups per molecule; and
(c) one or more non-sterically hindered amine functional curing agents having at least two non-sterically hindered amine functional groups per molecule.
11. A composite or an adhesive comprising a cured resin of the curable composition of claim 1.
12. A process of forming a composite comprising:
(I) admixing:
(a) at least one or more epoxy resins having an average of more than one glycidyl ether group per molecule;
((b) one or more sterically hindered amine functional curing agents having at least two sterically hindered amine functional groups per molecule; and
(c) one or more non-sterically hindered amine functional curing agents having at least two non-sterically hindered amine functional groups per molecule;
(II) impregnating a reinforcement comprised of glass fibers; and
(III) curing the curable composition at a temperature sufficient to cure the curable composition.
13. The process of claim 12, wherein the curing comprises a temperature of at least about 20\xb0 C.; and wherein the curing comprises two or more stages.
14. The process of claim 12, further comprising post-treating the composition by heating the composition to a temperature of at least about 70\xb0 C.
15. An adhesive, comprising a cured resin of:
(a) at least one or more epoxy resins having an average of more than one glycidyl ether group per molecule;
(b) one or more sterically hindered amine functional curing agents having at least two sterically hindered amine functional groups per molecule; and
(c) one or more non-sterically hindered amine functional curing agents having at least two non-sterically hindered amine functional groups per molecule.